Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119082 | 1.00 | PTGES (0.32) | PTGESORAI1KMT2AKDM4EATM | |
| SCHEMBL3113195 | 1.00 | PTGES (0.32) | PTGESORAI1KMT2AKDM4EATM | |
| SCHEMBL29416682 | 1.00 | PTGES (0.32) | PTGESORAI1KMT2AKDM4EATM | |
| Afoxolaner SCHEMBL18054743 | 0.94 | PTGES (0.33) | PTGESHPGDPOLB | |
| Esafoxolaner SCHEMBL18054742 | 0.94 | PTGES (0.33) | PTGESHPGDPOLB | |
| Afoxolaner SCHEMBL119580 | 0.94 | PTGES (0.33) | PTGESHPGDPOLB | |
| Afoxolaner SCHEMBL29367347 | 0.94 | PTGES (0.33) | PTGESHPGDPOLB | |
| Afoxolaner SCHEMBL29358921 | 0.94 | PTGES (0.33) | PTGESHPGDPOLB | |
| SCHEMBL21168921 | 0.94 | LMNA (0.32) | PTGESORAI1KDM4EFAP | |
| Esafoxolaner SCHEMBL29413811 | 0.94 | PTGES (0.33) | PTGESHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200061026-A1 | METHODS AND COMPOSITIONS FOR PREVENTING VECTOR-BORNE DISEASE TRANSMISSION | THE SCRIPPS RESEARCH INSTITUTE | 2020-02-27 | — | — | US | disclosed |
| WO-2018081733-A1 | METHODS AND COMPOSITIONS FOR PREVENTING VECTOR-BORNE DISEASE TRANSMISSION | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061026-A1 | METHODS AND COMPOSITIONS FOR PREVENTING VECTOR-BORNE DISEASE TRANSMISSION | PON1, TTPA, ACHE | PTGES 925/4885ORAI1 3442/4885KMT2A 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.